CLAIMS

1. A pharmaceutical package comprising a plastic container as primary packaging and a Nerve growth factor (NGF) aqueous formulation packaged therein, in which the plastic container has an inner surface in contact with the NGF aqueous formulation and an outer surface, wherein at least said inner contact surface is made of higher than 80% by weight of at least a propylene - ethylene copolymer having a melting enthalpy ΔHm less than 95 J/g and greater than 35 J/g, measured by DSC according to the method reported in the description.

2. The package according to claim 1 wherein the propylene – ethylene copolymer has a melting enthalpy ΔHm less than 90 J/g, preferably less than 80 J/g measured by DSC according to the method reported in the description.

3. The package according to claim 2 wherein the propylene – ethylene copolymer has a melting enthalpy ΔHm greater than 40 J/g, measured by DSC according to the method reported in the description.

4. The package according to any one of the previous claims wherein the propylene – ethylene copolymer has a melting temperature Tm lower than 160°C, preferably lower than 155°C, measured according to the DSC method reported in the description.

5. The package according to claim 4 wherein the propylene – ethylene copolymer has a melting temperature Tm higher than 130°C, more preferably higher than 140°C, measured according to the DSC method reported in the description.

6. The package according to any one of the previous claims wherein the propylene – ethylene copolymer is a random propylene – ethylene copolymer.

7. The package according to any one of the previous claims wherein the content of ethylene monomer in the propylene – ethylene copolymer is less than 40%, preferably less than 30%, and at least 5%.

8. The package according to any one of the previous claims wherein the container consists of the propylene – ethylene copolymer as defined in any one of the previous claims.

9. The package according to any one of the previous claims wherein the container is an ampoule, a vial, a bottle, a jar, a bag or a pouch, preferably is a vial or a bottle.

10. The package according to any one of the previous claims wherein the NGF aqueous formulation is an NGF aqueous solution, emulsion, suspension or lotion, preferably is a NGF aqueous solution, more preferably a NGF aqueous solution for ophthalmic use.

11. The package according to any one of the previous claims wherein, in the NGF aqueous formulation, NGF is present in amount from about 0.0001% to about 0.5% w/v, preferably from about 0.001% to about 0.10% w/v, most preferably of about 0.002% w/v of the aqueous formulation.

12. The package according to any one of the previous claims wherein, in the NGF aqueous formulation, NGF is recombinant human NGF (rhNGF).

13. The package according to any one of the previous claims wherein the NGF aqueous formulation is buffered with a biologically acceptable buffer to a pH between 6.8 to 7.5, preferably to a pH of about 7.2.

14. The package according to any one of the previous claims wherein the NGF aqueous formulation in addition to rhNGF comprises trehalose, mannitol, Methocel, PEG 6000, L-methionine, phosphate buffer, water and has a pH of about 7.2.

15. The package according to any one of the previous claims that is a mono-dose or a multi-dose package.

16. Use of a plastic container for packaging a NGF aqueous formulation, wherein the plastic container has an inner surface and an outer surface, wherein at least said inner surface is made of higher than 80% by weight of at least a propylene - ethylene copolymer having a melting enthalpy ΔHm less than 95 J/g and greater than 35 J/g, measured by DSC according to the method reported in the description.